Many countries report low initiation and continuation of PrEP. This doesn’t mean people don’t want the product. They might not want the program that’s offering it; or they might not be being reached. A “demand-creation cascade” such as the one proposed here for PrEP is one way to evaluate the program and the product. It would measure how many people received the full suite of demand-side activities the program hopes to deliver at a given stage. The precise set of steps would depend on the service-delivery design and strategy in question.
Towards a Demand Creation Cascade
Phases of Informed-Choice PrEP Counseling
This flow chart emerged from socio-behavioral research, including surveys and in-depth interviews with Kenyan and South African women. The research team set out with the goal of adapting the informed-choice approach used in family planning programs for use in PrEP, a prime example of fields learning from each other. The result is very clinic-centered; AVAC has added the column at the far right to reflect additional elements. However, it is a step towards much-needed exploration of how to make informed choice a reality in HIV prevention today.
Public Health is Personal
What gets measured gets funded, the adage goes. What would happen if communities demanded measurements of individual and collective health and well-being that have nothing to do with a retrovirus or a specific sex act, and everything to do with human dignity, comfort and safety in one’s own skin—a comfort that’s hard-fought in racist, sexist, homo– and trans-phobic nations? Imagine a world in which this cascade counted as much as 90-90-90. Let’s work to make it a reality.
Putting Women at the Center: Informed choice in 2018 and beyond
We need to give women the choice to use DTG or not and to use contraception if indicated and desired. We need to support choices across options, with risk reduction—not use of a specific product—as the primary outcome. We need to give women the choice to use DMPA-IM or –SC or not, and to use HIV prevention as desired.
AVAC Report 2018: No Prevention, No End!
AVAC’s 2018 annual state of the field report, No Prevention, No End! looks at today’s prevention crisis and offers context, analysis and strategy to turn that crisis around.
AVAC Report 2018 & HIV R4P
In this episode of Px Pulse, Ntando Yola, a veteran advocate and part of the Coalition to Accelerate and Support Prevention Research (CASPR) shares his advocacy priorities for R4P and beyond. But first, AVAC’s Emily Bass talks about the just-launched 2018 annual report from AVAC, this year titled No Prevention, No End!
Combination Prevention and AIDS 2018
In this episode, featuring Ambassador Deborah Birx, we take a look at one area of great importance that was center stage at the AIDS 2018 conference in Amsterdam: primary prevention.
Cure Research and Analytic Treatment Interruption
In this episode of Px Pulse, researchers and advocates debate the rationale, risks and ethics of interrupting treatment as part of cure research. This is known as analytic treatment interruption or ATI.
Oral PrEP Enrollment Snapshot
For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.
Global Investment in HIV Cure Research and Development in 2017
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2018, Global Investment in HIV Cure Research and Development in 2017: After Years of Rapid Growth Funding Increases Slow.